Copyright
©The Author(s) 2015.
World J Hepatol. Jan 27, 2015; 7(1): 101-112
Published online Jan 27, 2015. doi: 10.4254/wjh.v7.i1.101
Published online Jan 27, 2015. doi: 10.4254/wjh.v7.i1.101
Table 1 Palliative radiotherapy for hepatocellular carcinoma metastatic sites
| Ref. | Metastatic lesion treated | Patient (n) | Total dose, fraction size | Response | Median survival |
| Yamashita et al[122] (Retro) | LNs | 28 | 46-60 Gy, 2Gy | PR: 64%; CR: 18% | 13 mo |
| Zeng et al[29] (Retro) | LNs | 62 | 40-60 Gy, 2 Gy | PR: 37.1%; CR: 59.7% | 9.4 mo |
| He et al[121] (Retro) | Bone | 30 | 8-60 (median 40) Gy | 96.7% pain relief | 8.6 mo |
| Seong et al[26] (Retro) | Bone | 51 | 12.5-50 (median 30) Gy | 73% pain relief | 5 mo |
| Kaizu et al[123] (Retro) | Bone | 57 | 20-65 (mean 43) Gy | 83.8% pain relief | 6 mo |
- Citation: Kalogeridi MA, Zygogianni A, Kyrgias G, Kouvaris J, Chatziioannou S, Kelekis N, Kouloulias V. Role of radiotherapy in the management of hepatocellular carcinoma: A systematic review. World J Hepatol 2015; 7(1): 101-112
- URL: https://www.wjgnet.com/1948-5182/full/v7/i1/101.htm
- DOI: https://dx.doi.org/10.4254/wjh.v7.i1.101